Skip to main content

Table 1 Baseline characteristics for all eligible patients in the REVEAL study

From: Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study

  Treatment Group  
  Adalimumab (N = 808) Placebo (N = 397) P-value 1
Age (yrs), mean ± SD1 44.1 ± 13.2 45.4 ± 13.4 0.1177
Sex, n (% female)1 266 (32.9) 141 (35.5) 0.3996
Race, n (%)2    0.5432
   White 738 (91.3) 358 (90.2)  
   Black 27 (3.3) 20 (5.0)  
   Asian 21 (2.6) 7 (1.8)  
   American Indian/Alaska Native 3 (0.4) 1 (0.3)  
   Other 19 (2.4) 11 (2.8)  
Ethnicity, n (%)2    0.3434
   Not Hispanic or Latino 754 (93.3) 364 (91.7)  
   Hispanic or Latino 54 (6.7) 33 (8.3)  
Psoriasis history    
   Duration of psoriasis (yrs), mean ± SD1 18.6 ± 12.0 18.8 ± 12.0 0.7309
   Concomitant psoriatic arthritis, (% yes)2 222 (27.5) 113 (28.5) 0.7326
   Prior systemic psoriasis therapy, (% yes)2 260 (32.2) 128 (32.2) 1.0000
Psoriasis baseline assessments    
   Percentage of body surface area affected by psoriasis, mean ± SD2 25.8 ± 15.5 25.6 ± 14.8 0.8796
   Psoriasis Area and Severity Index, mean ± SD2 19.0 ± 7.1 18.8 ± 7.1 0.7787
Physician's global assessment score, n (% yes) 2    1.0000
   Moderate2 416 (51.5) 219 (55.2)  
   Severe 341 (42.2) 155 (39.0)  
   Very severe 51 (6.3) 23 (5.8)  
  1. 1t-Test.
  2. 2Fisher exact test or chi-square test.
  3. 3P-value for comparison between adalimumab versus placebo.